Exclusive Summary

• First-in-Class Therapy Targeting the Blockbuster Ischemic Stroke Market: UB434 is a pioneering, cell-free, non-exosomal stem cell-derived protein biologic addressing the massive clinical void for post-stroke neuro-restoration and functional recovery.
• Breakthrough Pan-Stage Efficacy Powered by Early Human Validation: Preclinical data shows a ~50% reduction in acute infarct volume, while ongoing human IITs have demonstrated profound disease-modifying effects, enabling severely paralyzed post-stroke patients to regain independent motor function.
• Scalable CMC and Exceptional Delivery Overcoming Traditional Biologic Limitations: Administered intravenously (IV) with excellent blood-brain barrier penetration, it features a highly standardized, stable manufacturing process that lowers COGS by 60-80% compared to typical cell therapies, maximizing global out-licensing and commercial potential.

Asset Materials

Contact Us for Full Materials